ArticleThe Iowa orthopaedic journal2026
Patterns and Timing of Local Recurrence in Benign Bone Tumors.
Article in The Iowa orthopaedic journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Benign bone tumors represent a heterogeneous group of nonmalignant lesions often treated surgically when symptomatic or at risk of fracture. Although local recurrence is a recognized risk, comparative data on recurrence timing and presentation across histologies are limited, contributing to the lack of standardized surveillance. We aimed to examine locally recurrent benign bone tumors after surgery to define recurrence patterns by histology. Methods: We conducted a single-center retrospective cohort study of 329 curative-intent procedures for benign bone tumors at the University of Iowa Hospitals and Clinics (2010-2024). Included histologies were giant cell tumor (GCT), aneurysmal bone cyst (ABC), unicameral bone cyst (UBC), osteoid osteoma (OO), chondroblastoma (CB), osteoblastoma (OB), non-ossifying fibroma, and chondromyxoid fibroma. Recurrence was defined by histology or characteristic imaging. The primary outcome was mode of recurrence presentation (symptomatic vs. radiographic). Secondary outcomes included time to recurrence and recurrence by bone filler type. Analyses used Wilcoxon rank-sum, Fisher's exact, and Spearman correlation tests. Results: Forty-two recurrences (12.8%) were identified. Recurrence presentation varied by histology (p = 0.001): OO and OB recurred exclusively symptomatically (100%), CB mostly symptomatically (66.7%), while ABC (20.0%), UbC (21.1%), and GCT (37.5%) recurred predominantly asymptomatically. No recurrences occurred for non-ossifying fibroma or chondromyxoid fibroma. Recurrence timing was not associated with age, sex, tumor site, or surgical method. In GCT treated with curettage, recurrence was more common with allograft than cement (33.3% vs. 3.4%, p = 0.007). OB and OO recurred earliest, with 100% and 83.3% in the first year, respectively. By year three, all OO and most GCT, ABC, and UBC recurrences had occurred; by year five, all tumors except a single CB had fully recurred. Conclusion: Recurrence patterns in benign bone tumors are strongly influenced by histology. OO and OB recur symptomatically within the first year, suggesting limited need for routine imaging. UBC, GCT, and ABC often recur asymptomatically, justifying structured imaging surveillance for 3-5 years. Cement use in GCT may reduce recurrence risk compared with allograft. Level of Evidence: III.
Indexed as
Identifiers
42516348PMC13403723What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.